Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Grant directs a Blood-brain Barrier Translational Laboratory focusing on enhancing drug delivery to brain tumors in children.
Interventions for Convergence Insufficiency in Concussed Children
The ICONICC Study is a randomized controlled clinical trial designed to compare the
proportion of successful treatment outcomes between children assigned to standard concussion
care only, standard concussion care plus simple convergence procedures, or standard
concussion care plus office-based vergence/accommodative therapy in children aged 11 to 17
years with symptomatic post-concussion syndrome. Children with post-concussion syndrome (4-12
weeks post-concussion injury) and symptomatic CI will be randomized to a 12-week treatment
program of either standard concussion care (SC), SC plus simple convergence procedures (SC+),
or SC plus office-based vergence/accommodative therapy SC+OBVAT (1:1:1 ratio).
The study will also compare the effect of treatment on clinical measures of both
accommodation and vergence, symptom level/burden, health-related quality of life, clinical
measures of saccadic eye movement, and objective eye movement measurements of disparity
vergence, saccadic function, and accommodative function. The attainment of objective eye
movement measures provides an opportunity to understand the underlying neurophysiology of the
vergence and accommodative systems. Objective eye movement recordings are powerful because of
the rich foundation from primate single-cell recordings that show a direct correlation with
vergence and accommodative parameters in the supraoculomotor area of midbrain2, 3 and the
oculomotor vermis of the cerebellum.4, 5 Thus, a combined approach of acquiring both clinical
vision function measures and objective eye movement recordings in children with PCS-CI may
lead to better characterization of the oculomotor phenotype with subsequent improved and
personalized therapeutic interventions.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details
In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI
This pilot early phase I trial studies how well ferumoxytol-enhanced magnetic resonance
imaging (MRI) correlates with inflammatory (macrophage) responses in pediatric patients with
malignant brain tumors. If there is good correlation, ferumoxytol-enhanced MRI can serve as a
noninvasive imaging biomarker of inflammation.